ISB- Isolated small bowel Tx; SB-L - Small bowel-Liver Tx; MV- Multivisceral transplant.

Study & Type	Sample size Patient characteristics.	Type of Tx & Protocol	Patient Survival	Graft Survival/weaned from TPN/Hospital stay	Adverse events/complications
Nucci A et al. Long-term nutritional outcome after pediatric intestinal transplantation. J Ped Surg 2002;37:460-63. Children’s Hospital of Pittsburgh, U of Pittsburgh Med Centre Registry	N=24 pediatric pts 82% male median age 3.2 yrs (8.5 months -17.4 yrs) 75% diagnosed as surgical short bowel syndrome. All dependent on TPN @ time of transplant 44% receiving some form of enteral nutrition before Tx.	ISB = 8 L-SB = 13 MV = 3	Cumulative survival rate 1-yr = 91.3% 2 yrs = 86.2% Cumulative survival rage for those weaned from TPN 1-yr = 100% 1-yr = 94.1%	87% weaned from TPN to an AA or peptide-based enteral formula or solid food within 3 months. 1 or more food allergies developed in 4% of pts (milk allergy common to all, egg allergy in 50%) Anthropometric & lab data Positive trend in Z-scores for weight & height observed in only 39% & 22% of pts respectively. Comparison of baseline & 1 yr height/length showed statistical significance (p=0.01) indicating a decrease in growth velocity over time. -Positive correlation observed between albumin level & linear growth velocity.	Mild to moderate eosinophilic gastroenteritis was diagnosed in 48% of patients as early as 1 month post-Tx. Rejection & infection 1 pt had evidence of mild acute rejection and 1 had concurrent EBV infection. Remaining pts showed no evidence of rejection or infection.
Kato T et al Intestinal Transplantation at the University of Miami. Transpl Proc. 2002;34:868. June 1994 - August 2001 Retrospective analysis University of Miami School of Medicine	N = 111 patients (120 allografts) Divided into 3 periods: Period I June 1994 - Dec 1997 = 44 pts Period II June 1998 - Jan 2000 = 53 pts Period III Jan 2001 - August 2001 = 23 pts 47 (39%) adults and 61% children Indications for Tx in Children Gastroschisis 24% Necrotizing enterocolitis 24% Volvulus 14% Intestinal atresia 13% Hirschsprung’s disease 6%	ISB = 38 grafts L-SB = 33 grafts MV = 49 grafts Technical modifications Systemic drainage of bowel graft (16), inclusion of pancreaticoduodenal complex in L-SB tx, reduced size graft, separate partial liver & partial intestinal grafts (4) MV tx without liver (6) For period II & III Daclizumab was used exclusively in period II and Campath-1H used in adults in period III. Tacrolimus and corticosteriods were used as baseline immunosuppression in all cases. CMV positive grafts were used regardless of recipient serology in period II & III	Overall 6 months survival Period I = 53% Period II = 79% Period III = 89% Overall 1 year survival Period I = 48% Period II = 66% Period III = ongoing Univariate analysis and multivariate analyses showed that patient age, graft types, period and presence of concomitant liver failure were not significant predictors of outcome. Transplantation in recent period (p=0.037) and the presence of concomitant liver failure (p=0.015) were both statistically significant. (multivariate analysis p =0.031 &0.052)	Conclusion: The results of intestinal transplantation have continued to improve due to technical innovations and advances in postoperative management. Patients who were free of liver failure at the time of transplantation appeared to have a better outcome.	Indications for adults: Mesenteric thrombosis 33% Desmoid tumor & Gardner’s syndrome 17%, Crohn’s disease 11% Trauma 15% Chronic pseudo obstruction 11% Volvulus 4% Others 9%
	Megacystis microcolon & psuedoobstructi on 11% Microvillus inclusion disease 5% Others 3%	Graft surveillance examination with a zoom endoscope was introduced in periods II & III but only as need in period I.